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Endocrine assessment ofimpotence - pitfalls ofmeasuring
serum testosterone without sex-hormone-binding globulin
K.J. Hardy and J.R. Seckl
Department ofEndocrine and Metabolic Diseases, Metabolic Unit, Western General Hospital,
Crewe Road, Edinburgh EH4 2XU, UK
Summary: The pitfalls ofmeasuring only total serum testosterone are illustrated by a 52 year old man
whose hyperprolactinaemia was associated with normal total serum testosterone but a raised sex-
hormone-binding globulin, giving a low free testosterone. Prolactin suppression with bromocriptine
normalized sex-hormone-binding globulin and free testosterone, and restored potency and energy after 30
years of impotence and tiredness.
Introduction
Impotence is a common and distressing symptom
that may present to general practitioners or to a
variety of different specialists.'`3 To highlight the
need for full endocrinological assessment of
patients with impotence, we report a 52 year old
man with a 30 year history of impotence whose
total serum testosterone was misleadingly normal,
but whose free testosterone was low by virtue of his
raised sex-hormone-binding globulin (SHBG)
levels. Treatment of his microprolactinoma nor-
malized SHBG and free testosterone, and restored
potency. Endocrinological assessment of impo-
tence should include calculation of free testos-
terone by measurement of SHBG.
Case report
A 52 year old man was referred to a urologist by his
general practitioner with a 4-year history oferectile
failure. Direct questioning revealed that he had
been impotent for 30 years, achieving only partial
erections after protracted foreplay. He was able to
ejaculate normally (he had fathered three children).
He and his wife had volunteered the problem once
before, 4 years earlier, when they had received
psychosexual counselling (without investigation)
to no avail. Over the years he had been investigated
for a variety of vague somatic symptoms domi-
nated by profound tiredness and weakness. On
assessment, he was being treated with clomi-
pramine 25 mg thrice daily for tiredness presumed
to be secondary to depression. Urological examina-
tion was unremarkable but he was found to have an
elevated serum prolactin of 2343 mU/l. Clomi-
pramine was stopped but his symptoms were not
improved so he was referred to an endocrinologist.
On endocrinological assessment, 6 months after
stopping clomipramine, the patient's impotence
was unchanged. He considered his libido to be
normal, and denied headache, breast enlargement
or tenderness, galactorrhoea, reduced beard
growth, skin change, or postural dizziness. On
examination he was noted to have very fine facial
skin. There were no features ofCushing's disease or
acromegaly, there was no gynaecomastia or galac-
torrhoea, and no postural hypotension. His penis
was normal, and both testes were firm and of
normal volume. He was not obviously depressed.
Total thyroxine and thyrotrophin were normal at
94 (reference range 60-145) nmol/l and 2.0
(reference range 0.1-5.5) mU/l, respectively. Cor-
tisol rose after 250 ,Lg tetracosactrin from 486 to
821 (normal> 550) nmol/l, andb gonadotrophins
and oestradiol were within the quoted normal
range, follicle stimulating hormone 6.7 U/l,
luteinizing hormone (LH) 3.2 (reference range for
both 1.5-9.0) U/l, oestradiol 97 (reference range
<200) pmol/l. Serum prolactin was markedly
elevated at 2,390 (reference range 60-390) mU/I,
and although total testosterone was normal at 11.2
(reference range 10-30) nmol/l, SHBG was high at
57 (reference range 6-45) nmol/l, giving a low free
testosterone of 19.5 (reference range > 22) nmol/l.
Visual fields were full but pituitary magnetic
resonance imaging suggested a microadenoma. He
was treated with the dopamine agonist bromocrip-
tine 2.5 mg thrice daily, which within 6 weeks
normalized prolactin to 88 mU/I. Total testost-
erone increased to 23.0 nmol/I and SHBG fell,
giving a normal free testosterone of 34 nmol/l. At
this time the patient's chronic tiredness had
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resolved, his libido was increased, and for the first
time in 30 years, he was able to sustain normal
erections.
Discussion
Impotence may be defined as inability to attain an
erection of sufficient rigidity for vaginal penetra-
tion in 50% or more of attempts.4 Erectile
insufficiency after a period of normal sexual func-
tioning is referred to as secondary impotence.
Despite his 30-year history of impotence, our
patient was rapidly improved after identification
and treatment of his hyperprolactinaemia. This
illustrates several important points about the man-
agement of impotence. Impotence, even of many
years' duration, may not be volunteered by patients
and cannot be excluded by the patient's ability to
father children. Impotence should never be dis-
missed as being ofpsychological origin without full
examination and adequate endocrine assessment.
General assessment should include a search for
diabetes, vascular disease, neuropathy, uraemia,
occult malignancy (especially prostate carcinoma),
haemochromatosis and drug and alcohol history.
Assessment should also be made for androgen
deficiency: loss of libido, loss of muscle bulk, and
loss of secondary sexual hair, together with voice
change, fine skin and reduced testicular volume. A
search should be made for causes of primary and
secondary gonadotrophin deficiency, such as Kall-
man's syndrome, acromegaly and Cushing's
disease. As well as random blood glucose, electro-
lytes, liver function tests, and investigations
prompted by physical signs, thyroid function,
gonadotrophins, prolactin and serum testosterone
should always be measured.
This patient illustrates well the occasional pitfall
of relying on total serum testosterone (which was
within the reference range) when androgen de-
ficiency is suspected. Sex-hormone-binding
globulin is androgen-regulated and therefore often
raised when testosterone is low.5 As in this case,
total serum testosterone may be normal while free
testosterone is unequivocally low. Measurement of
SHBG with calculation of free testosterone will
avoid this problem. Hyperprolactinaemia causes
suppression of the hypothalamic-pituitary-
gonadal axis perhaps by opioid-mediated inhibi-
tion of normal pulsatile secretion of LH,6 the
stimulus to testosterone secretion by Leydig cells.
Gonadotrophin levels within the reference range in
the presence oflow free testosterone, in this patient,
were inappropriate and suggest a hypothalamic or
pituitary cause for his androgen deficiency. Bromo-
criptine, by virtue of its dopamine agonist proper-
ties, inhibits prolactin secretion by lactrotrophs
and usually restores prolactin levels to normal.7
Not only was our patient's impotence cured by
treatment of his hyperprolactinaemia, but his long-
standing weakness and tiredness (presumably
secon-dary to chronic androgen deficiency) also
responded to normalization of testosterone with
bromocriptine.
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